» Articles » PMID: 24186882

Burden of Diabetic Foot Ulcers for Medicare and Private Insurers

Overview
Journal Diabetes Care
Specialty Endocrinology
Date 2013 Nov 5
PMID 24186882
Citations 207
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To estimate the annual, per-patient incremental burden of diabetic foot ulcers (DFUs).

Research Design And Methods: DFU patients and non-DFU patients with diabetes (controls) were selected using two de-identified databases: ages 65+ years from a 5% random sample of Medicare beneficiaries (Standard Analytical Files, January 2007-December 2010) and ages 18-64 years from a privately insured population (OptumInsight, January 2007-September 2011). Demographics, comorbidities, resource use, and costs from the payer perspective incurred during the 12 months prior to a DFU episode were identified. DFU patients were matched to controls with similar pre-DFU characteristics using a propensity score methodology. Per-patient incremental clinical outcomes (e.g., amputation and medical resource utilization) and health care costs (2012 U.S. dollars) during the 12-month follow-up period were measured among the matched cohorts.

Results: Data for 27,878 matched pairs of Medicare and 4,536 matched pairs of privately insured patients were analyzed. During the 12-month follow-up period, DFU patients had more days hospitalized (+138.2% Medicare, +173.5% private), days requiring home health care (+85.4% Medicare, +230.0% private), emergency department visits (+40.6% Medicare, +109.0% private), and outpatient/physician office visits (+35.1% Medicare, +42.5% private) than matched controls. Among matched patients, 3.8% of Medicare and 5.0% of privately insured DFU patients received lower limb amputations. Increased utilization resulted in DFU patients having $11,710 in incremental annual health care costs for Medicare, and $16,883 for private insurance, compared with matched controls. Privately insured matched DFU patients incurred excess work-loss costs of $3,259.

Conclusions: These findings document that DFU imposes substantial burden on public and private payers, ranging from $9-13 billion in addition to the costs associated with diabetes itself.

Citing Articles

Brown adipose tissue transplantation ameliorates hindlimb ischemic damage in diabetic mice.

Lu T, Liu A, Li C, Li Y, Yang B, Liu Q Sci Rep. 2025; 15(1):8820.

PMID: 40087510 DOI: 10.1038/s41598-025-93261-5.


Cost-Effectiveness Analysis for Managing Diabetic Foot Ulcer (DFU) in USA: Platelet-Rich Plasma (PRP) vs Standard of Care (SoC).

Russo S, Landi S, Simoni S Clinicoecon Outcomes Res. 2025; 17:157-169.

PMID: 40078326 PMC: 11900793. DOI: 10.2147/CEOR.S496616.


Analysis of risk factors for foot ulcers in diabetes patients with neurovascular complications.

Fan Z, Liu Y, Xie H, Yang Q, Zhang G, Zhang P BMC Public Health. 2025; 25(1):792.

PMID: 40011841 PMC: 11866585. DOI: 10.1186/s12889-025-21639-1.


In-Situ Electrospinning Dressings Loaded with Kaempferol for Reducing MMP9 to Promote Diabetic Ulcer Healing.

Li J, Meng H, Guo W, Zhou L, Wu S, Gao G Int J Nanomedicine. 2025; 20:1101-1117.

PMID: 39895983 PMC: 11786600. DOI: 10.2147/IJN.S501370.


Comparing the Efficacy of a Unique Advanced Bioengineered Type-I Collagen-Based Skin Substitute Versus an Amnion Graft With Standard of Care in the Treatment of Non-healing Diabetic Foot Ulcers: A Randomized Clinical Trial.

Armstrong D, Hanft J, Surprenant M, Isaac A, Carter M, Zelen C Cureus. 2025; 17(1):e78021.

PMID: 39872922 PMC: 11769781. DOI: 10.7759/cureus.78021.